Tag: anetumab ravtansine
Anetumab Ravtansine Demonstrates Encouraging Preliminary Antitumor Activity in Heavily Pretreated Mesothelin-expressing...
In a phase I clinical trial, the investigational antibody-drug conjugate (ADC) anetumab ravtansine (BAY 94-9343; Bayer) shows promising antitumor activity in heavily pretreated patients with...
Anetumab Ravtansine does not meet Primary Endpoint in Second-Line Mesothelioma
A Phase II clinical trial evaluating its anetumab ravtansine, also known as BAY 949343, as a monotherapy in patients with recurrent malignant pleural mesothelioma...
Clinical Updates Confirming Advances and Meaningful Benefits for Patients
Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...
ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...
Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...
